LIG1 Loss Reveals Targetable Weakness Against Chemotherapy-Resistant Triple-Negative Breast Cancer
In triple-negative breast cancer (TNBC) that carries TP53 mutations, loss of one copy of the DNA ligase I gene (LIG1) ...
In triple-negative breast cancer (TNBC) that carries TP53 mutations, loss of one copy of the DNA ligase I gene (LIG1) ...
A groundbreaking study has unveiled new insights into the complex biology of cancer-associated fibroblasts (CAFs) within triple-negative breast cancer (TNBC), ...
In a groundbreaking phase 2 clinical trial, researchers have demonstrated the efficacy of olaparib, a PARP inhibitor, in treating metastatic ...
In a groundbreaking study poised to reshape the therapeutic landscape of aggressive breast cancers, researchers have uncovered a novel metabolic ...
In a groundbreaking study published in the Journal of Translational Medicine, researchers Li, Chen, and Wang lead an exploration into ...
Triple-negative breast cancer (TNBC) remains one of the most formidable challenges in oncology due to its aggressive nature and its ...
In a groundbreaking study unveiled recently, researchers have illuminated the complex metabolic dependencies underpinning triple-negative breast cancer (TNBC), highlighting a ...
Triple-negative breast cancer (TNBC) is notorious for its aggressive nature and resistance to conventional therapies, creating an urgent need for ...
Triple-negative breast cancer (TNBC) remains one of the most challenging subtypes of breast cancer to treat effectively. Defined by the ...
In a groundbreaking study published in Nature Communications, researchers have revealed a crucial genetic link that increases susceptibility to a ...
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine